Antibe Therapeutics Inc. (TSE:ATE) Director John Lawrence Wallace Sells 21,500 Shares
Antibe Therapeutics Inc. (TSE:ATE) Director John Lawrence Wallace Sells 21,500 Shares
Antibe Therapeutics Inc. (TSE:ATE – Get Rating) Director John Lawrence Wallace sold 21,500 shares of Antibe Therapeutics stock in a transaction on Thursday, July 7th. The stock was sold at an average price of C$0.62, for a total transaction of C$13,330.00. Following the sale, the director now directly owns 1,899,576 shares of the company's stock, valued at C$1,177,737.12.
安提贝治疗公司(多伦多证券交易所代码:ATE-GET评级)董事约翰·劳伦斯·华莱士在7月7日星期四的一笔交易中出售了21,500股安提伯治疗公司的股票。该股以0.62加元的平均价格出售,总成交金额为13,330.00加元。交易完成后,董事现在直接持有该公司1,899,576股股票,价值1,177,737.12加元。
TSE ATE opened at C$0.62 on Wednesday. Antibe Therapeutics Inc. has a 52-week low of C$0.59 and a 52-week high of C$3.65. The company has a debt-to-equity ratio of 0.29, a quick ratio of 11.92 and a current ratio of 13.07. The company has a market capitalization of C$31.86 million and a P/E ratio of -1.16. The company has a fifty day moving average of C$0.66 and a 200-day moving average of C$0.70.
周三,Tse ATE开盘报0.62加元。安提贝治疗公司的股价跌至0.59加元的52周低点和3.65加元的52周高点。该公司的负债权益比率为0.29,速动比率为11.92,流动比率为13.07。该公司市值为3,186万加元,市盈率为-1.16。该公司的50日移动均线切入位在0.66加元,200日移动均线切入位在0.70加元。
Antibe Therapeutics Company Profile (Get Rating)
安提贝治疗公司简介(获取评级)
Read More
阅读更多内容
- Should These Two Airlines Be In Your Portfolio?
- Old Dominion Freight Line (ODFL): This Dividend Growth Stock Deserves Your Attention
- Is There a Reasonable Price to Buy Stitch Fix Stock?
- 3 Smid Caps Under $20 Set to Recover
- Continuining to Assess Tesla's Future As The EV Market Becomes Increasingly Competitive
- 这两家航空公司应该在你的投资组合中吗?
- Old Dominion Freight Line(ODFL):这只红利成长股值得你关注
- 是否有一个合理的价格购买缝纫机修理股票?
- 3个20美元以下的SmidCaps将回升
- 随着电动汽车市场竞争日益激烈,继续评估特斯拉的未来
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
接受《安提贝治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对安替比治疗公司和相关公司的最新新闻和分析师评级的每日简要摘要。